AD 313

Drug Profile

AD 313

Alternative Names: AD-313

Latest Information Update: 11 May 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SkyePharma PLC; Sosei R&D
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease

Most Recent Events

  • 11 May 2005 Discontinued - Preclinical for Chronic obstructive pulmonary disease in United Kingdom (Inhalation)
  • 21 Jan 2004 Preclinical trials in Chronic obstructive pulmonary disease in United Kingdom (Inhalation)
  • 26 Jul 2001 Arakis is collaborating with SkyePharma PLC to develop AD 313
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top